NIH peer review: An inside look

What are the most important questions and technologies that will hit your discipline within the next 10 years? Do you believe your NIH grant applications are aligned in the most appropriate study sections? Should grant reviewers serve as mentors to applicants? Last month, I sat down with Antonio Scarpa, director of the Center for Scientific Review, the gateway for all NIH grant applications, to discuss these and other questions. The occasion was the agency's final open house, during which biome

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
What are the most important questions and technologies that will hit your discipline within the next 10 years? Do you believe your NIH grant applications are aligned in the most appropriate study sections? Should grant reviewers serve as mentors to applicants? Last month, I sat down with Antonio Scarpa, director of the Center for Scientific Review, the gateway for all NIH grant applications, to discuss these and other questions. The occasion was the agency's final open house, during which biomedical researchers flew from all corners of the country to Bethesda, Maryland, to linkurl:talk about;http://www.the-scientist.com/blog/display/54034/ how they think NIH peer review should change. There was a lot of discussion and debate, but little resolution. "Nothing has been decided," linkurl:Scarpa;http://cms.csr.nih.gov/AboutCSR/Welcome+to+CSR/ noted. "Should the study section essentially tell how to do the experiment, helping write an application? If you do that, it could be a completely different mechanism," he said. Also, should the agency place a cap on the number of applications one researcher can receive, to prevent monopolizations? One of Scarpa's goals is to remake peer review as a benefit, not a burden, for reviewers. This was lost five years ago, he says, when reviewers themselves began struggling for funding and spending months writing grants. At a minimum, reviewers dedicate weeks to combing through the thousands of applications that come in; asking them to do both that and maintain their research places a "stress on the system." Scarpa also addressed a startling statistic that recently emerged: The average age at which investigators receive their first independent NIH grant is 42.9 years. What concerns him more, however, are linkurl:projections released by the NIH;http://www.nih.gov/about/director/acd/12072007slides/zerhouni_acd_12072007.pdf in December of the age distribution of PIs in the coming years. The average age at obtaining grants will continue to rise, and PIs will apply for grants later and later in life, meaning scientists may soon be struggling well into their 50s and 60s. The CSR open house reviews are a separate process from the agency-wide NIH evaluation of peer review. You can click linkurl:here;http://www.the-scientist.com/news/display/54009/ to weigh in on changes the agency is considering, such as shortening applications. Last week, the NIH announced that peer reviewers linkurl:could submit grants;http://www.the-scientist.com/blog/display/54087/ outside of normal deadlines, to save them from having to simultaneously write and review applications. Click linkurl:here;http://images.the-scientist.com/supplementary/audio/11108.mp3 to listen to excerpts from my interview with Scarpa, in which he talks about his biggest concerns about NIH peer review, and the agency's influence on other health research budgets worldwide. Next week, we will publish an interview with Lawrence Taybak, who is spearheading the agency-wide review of NIH peer review.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Alison McCook

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo